Carole A. Sable, M.D.
Carole is a clinical development expert with many years’ experience in the biotech and pharmaceutical industries. Most recently, she was CMO at Vitae Pharmaceuticals, Inc. prior to the acquisition by Allergan Plc. Earlier she held the position of CMO at Revolution Medicines Plc. and prior to this was CMO at Scynexis, where she designed the development program for the antifungal SCY-078. Prior to this, Carole held various leadership positions across the infectious diseases and neuroscience therapeutic areas for Merck & Co. At Merck she oversaw NDA preparation for Suvorexant (BELSOMRA), and led the development of the antifungal caspofungin through its approval for multiple indications. Before Merck, Carole was CMO for Novexel SA (France), and President of Novexel, Inc. (USA), a biotech company specializing in the discovery and development of antibiotics. At Novexel, Carole designed and managed the development program for ceftazidime-avibactam through successful Phase 2B trials, the design of the first resistant pathogen study, and the acquisition of the company by Astra Zeneca. Carole is an Infectious Diseases specialist trained at the University of Virginia and earned a Doctor of Medicine from Jefferson Medical College.
David Lathbury, Ph.D.
David has over 20 years’ experience in the Pharmaceutical arena where he has worked for SmithklineBeecham and later AstraZeneca where he was Director of Process Chemistry. Most recently he was Vice President of Chemical Development at AMRI. During his career, he has worked on 4 marketed drugs including process re-development activities on “Seroquel” and “Paxil”. During his time at AstraZeneca, his team was responsible for the chemical development of” Iressa” and “Crestor”. He is author or co-author for over 40 publications and patents. He is fellow of the Royal Society of Chemistry and a visiting Professor at Bristol University. In 2012, he was Chair of the Gordon Research Conference on Heterocyclic Compounds.
Lloyd Czaplewski, Ph.D.
Dr. Czaplewski has >25-years of biopharmaceutical and NCE discovery and development experience from concept to clinical evaluation across multiple therapeutic areas – including anti-infective indications. He has built and then sold an antibacterial company, hired outstanding teams, created SABs and has raised >£25M from UK, Europe, USA and Japan including charities (Wellcome Trust), Government (DTI, UK & NIAID, USA), Corporate (Astellas) and VC investment groups. He is an inventor on >25 patents and has authored > 30 papers. He is currently the Founder and CEO of Abgentis Ltd which focuses on semi-synthetic aminocoumarin antibiotics; CSO of Persica Pharmaceutical Ltd which focuses on chronic back pain, and a Founder and Director of Chemical Biology Ventures Ltd which provides consulting services to biotech, academia, charities and investors. He recently chaired a review into Alternatives to Antibiotics for Wellcome and the Department of Health which informed the O’Neill Report and is involved in several antibiotic R&D initiatives including GARDP and its Antimicrobial Memory Recovery Initiative, Antibiotic Research UK, The Pew Trust’s Antibiotic Resistance Project and as a member of a CARB-X interview panel. Over the last 15 years, Lloyd has led the tendering process, contracting and project management of multiple antibacterial programmes through a variety of CROs e.g. microbiology (Evotec, Amtuit, LGC, Wuxi), in vitro ADMET (Cyprotex), pharmacology (Evotec, GVK Biosciences, Wuxi), Efficacy (Evotec, Wuxi, University of North Texas (Bill Weiss)), Formulation (Kuecept, Aptuit, Quay, Onyx, Critical Pharmaceuticals), medicinal chemistry and scale up to kilo lab (Evotec, Jubilant Chemsys, Key Organics, Biofocus, Aptuit, GVK Biosciences, Sai Advantium, SYNthesis Med Chem) and where necessary has developed key assays in house to inform optimisation programmes e.g. photostability, phototoxity and protein binding.
John Dixon, Ph.D.
Dr. Dixon has 36 years’ experience in industrial Pharmaceutical Research & Development in several therapeutic areas. He was Head of Medicinal Chemistry for 20 years at Fisons, and Vice President of Drug Discovery at AstraZeneca Charnwood for 9 years in charge of up to 450 scientific staff. As VP of AstraZeneca Charnwood he delivered 35 candidate drugs (mainly in the Respiratory & Inflammation areas, most of which were given by the inhaled route) several of which are in full clinical development. Brilinta, a potential blockbuster for thrombotic disorders, achieved widespread regulatory approval in 2010-2012. A second drug Cangrelor achieved all phase 3 endpoints in late 2012. A Fellow of the Royal Society of Chemistry and Member of the American Chemical Society he served on several professional and academic advisory committees and was awarded an honorary D.Sc. from Loughborough University in 2004 “for meritorious services to science and the community.”
Patrice Nordmann, M.D.
Prof. Nordmann is currently Head of the Molecular Microbiology Unit, Dept Medicine, University of Fribourg (Switzerland) of the French National Reference Center for Antibiotic Resistance, and of the INSERM research Unit “Emerging Antibiotic Resistance”, University Paris XI (France). He is a renowned expert in the field of antibiotic resistance, with a major focus on emerging resistance traits such as the worldwide spread of carbapenemases. Prof. Nordmann has co-authored more than 500 peer-reviewed publications in the field and is the recipient of prestigious awards such as the Louis Pasteur Medal from the French National Academy of Sciences (2012), the Excellence Microbiology and Infectious Diseases Award from the European Society for Microbiology and Infectious Diseases (2013) and the Antimicrobial Research Award from the American Society for Microbiology (2015).
Jean-Denis Docquier, Ph.D.
Dr. Docquier is an Associate Professor of Microbiology at the University of Siena (Department of Medical Biotechnologies) and has an educational background in biochemistry. His current research interests focus on the mechanism of resistance to antimicrobial agents in Gram-negative bacteria. His contribution in the field has been recognized by several academic awards. In collaboration with Industry and Academia, he has contributed several studies aiming at the preclinical characterization of novel antimicrobials and/or beta-lactamase inhibitors. Dr. Docquier is member of the editorial board of Antimicrobial Agents and Chemotherapy (ASM Press, Washington DC, USA) and member of the editorial advisory board of Biochemical Pharmacology (Elsevier, Oxford, UK).
José Francisco Garcia-Bustos, Ph.D.
José has managed international and interdisciplinary groups working in antimicrobial drug discovery at GSK and its legacy companies for 16 years. His areas of responsibility have included antibacterials, antifungals, antimalarials and antituberculars. Previously to joining GSK, José worked in academic positions doing research on bacterial cell walls and the mode of action of beta-lactams (The Rockefeller University, New York) and in yeast cell biology (Biozentrum of Basel University, Basel). He has contributed to the elucidation of the structure of pneumococcal cell wall peptidoglycan, the publication of the first drug resistant pneumococcal genome, the discovery of the molecular targets for the sordarin antifungals, the development and implementation of methods for large scale phenotypic screening in malaria and TB and the progression of antifungal (sordarin) and malaria (4-(1H)-pyridones) drug discovery projects to pre-clinical and clinical development. José is currently associate Professor of Microbiology at Monash University (Melbourne), where he is continuing work on antimalarial targets.